DICER1 D1709E

CI-VAR-00000430Explore in graph →CIViC 2196

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Ovarian Sertoli-Leydig Cell Tumor1
DICER1 D1709E	(predisposing)	Predisposing	C	Supports Predisposition	2	accepted	EID5888 DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E… (full text at CIViC) PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC	civic
Glandular Pattern Ovarian Yolk Sac Tumor1unmapped disease
DICER1 D1709E	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	accepted	EID5900 DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a somatic mutation in D1709E. PMID 22187960 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.